https://www.avient.com/news/avient-earns-luxe-pack-green-award-sustainability-initiative
The honor was given during the LUXE PACK New York trade show last week for Avient’s ongoing efforts to reduce scope 1 & 2 greenhouse gas (GHG) emissions.
Avient is certified ACC Responsible Care®, a founding member of the Alliance to End Plastic Waste and certified Great Place to Work®.
https://www.avient.com/knowledge-base/article/overmolding-solutions
There are a variety of Avient TPEs designed to have excellent adhesion to a number of rigid plastic substrates for overmolding.
Our Dynaflex™ G 7900 Series and OnFlex™ S EH Series are great starting places for your polypropylene overmolding application.
https://www.avient.com/news/avient-launches-new-bio-based-polymer-solutions-medical-and-pharmaceutical-applications-during-pharmapack-europe-2022
Documented change control beyond CAS number is practiced and Registered Drug Master File (DMF) / Device Master File (MAF) documentation is maintained.
Avient employs approximately 8,700 associates and is certified ACC Responsible Care®, a founding member of the Alliance to End Plastic Waste and certified Great Place to Work®.
https://www.avient.com/sites/default/files/2021-10/microbial-susceptibility-of-various-polymers-and-evaluation.pdf
In brief, 3.8-cm2 test pieces were prepared and placed in intimate contact with tryptic soy agar.
Test samples 3.8 cm2 were placed in intimate contact with nutrient salts agar.
More notably, however, ZPT-loaded samples demonstrated a clear reduction in the average number of CFUs after 24 h.
https://www.avient.com/knowledge-base/article/securing-supplies-medical-plastic-solutions?rtype[]=1164
During the Covid-19 pandemic, it has become apparent that globalization raises a number of issues.
Companies placing medical devices and packaged pharmaceuticals on the market need their products to comply with healthcare standards, no matter where their products are sold and no matter where they procure their raw materials.
All Mevopur production sites offer change control agreements beyond Chemical Abstracts Service (CAS) number.
https://www.avient.com/knowledge-base/article/securing-supplies-medical-plastic-solutions?pname[]=17814
During the Covid-19 pandemic, it has become apparent that globalization raises a number of issues.
Companies placing medical devices and packaged pharmaceuticals on the market need their products to comply with healthcare standards, no matter where their products are sold and no matter where they procure their raw materials.
All Mevopur production sites offer change control agreements beyond Chemical Abstracts Service (CAS) number.
https://www.avient.com/knowledge-base/article/securing-supplies-medical-plastic-solutions
During the Covid-19 pandemic, it has become apparent that globalization raises a number of issues.
Companies placing medical devices and packaged pharmaceuticals on the market need their products to comply with healthcare standards, no matter where their products are sold and no matter where they procure their raw materials.
All Mevopur production sites offer change control agreements beyond Chemical Abstracts Service (CAS) number.
https://www.avient.com/sites/default/files/2020-10/tpe-overmold-design-guide.pdf
TPE Substrate TPE Substrate Figure 2.
They should be placed in the direction of the feeding flow front and at the base of the sprue (Figure 8).
They should be placed in the direction of the feeding flow front and at the base of the sprue (Figure 8).
https://www.avient.com/sites/default/files/2023-07/AVNT Q2 2023 Earnings Presentation%5B70%5D.pdf
AVIENT CORPORATION S E C O N D Q U A R T E R 2 0 2 3 R E S U L T S (NYSE: AVNT) J U LY 2 7 , 2 0 2 3 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
They are based on management’s expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements.
GUIDANCE (TOTAL COMPANY) 8 15.4% 15.9% Guidance Actual Adjusted EBITDA Margin % Better-than-expected margins driven by: • Favorable mix - strong demand for composite applications • Raw material deflation Q2 EBITDA BRIDGE (TOTAL COMPANY) 9 ($ millions) CAI: Price / Mix 7) Deflation 11) SEM: Price / Mix 2) Deflation 6) Net Price Benefit 26) Wage and Energy Inflation (10) Cost Reductions 13) FX (2) Q2 2023 Actual $131) Adjusted EBITDA Q2 2022 Pro Forma $ 172) Demand (68) • Demand conditions vs. expectations: US & Canada LATAM EMEA Asia • Net price benefit remains greater than wage and energy inflation • Clariant synergies and reduced administrative costs Q2 2023 SEQUENTIAL SALES BY REGION Q 2 2 0 2 3 v s .
https://www.avient.com/sites/default/files/resources/Ramos%2520IATF%252016949-2016%2520exp%25207-10-2021_0.pdf
For and on behalf of BSI: Carlos Pitanga, Chief Operating Officer Assurance – Americas Certification Date: 2018-07-11 Latest Issue: 2018-07-11 Expiry Date: 2021-07-10 BSI Certificate Number: 85585 IATF Number: 0315491 Page: 1 of 2 This certificate remains the property of BSI and shall be returned immediately upon request.
IATF Contracted Office: BSI Assurance UK Limited, registered in England under number 7805321 at 389 Chiswick High Road, London W4 4AL, UK.
Including the following remote support functions: Polyone Corporation 33587 Walker Road Avon Lake, OH 44012 USA Audited by ABS Quality evaluations Product Design, Purchasing, Customer Service and Strategic Planning Location Registered Activities BSI Certificate Number: 85585 IATF Number: 0315491 Certification Date: 2018-07-11 Latest Issue: 2018-07-11 Expiry Date: 2021-07-10 Page: 2 of 2 This certificate remains the property of BSI and shall be returned immediately upon request.